Clinical Trials · NCT00616408

Prediction of Tumor Shrinkage in Acromegaly

Name: Prediction of Tumor Shrinkage in Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AOctreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Federico II University
Enrollment: 61
Start date: Jan 1997
Locations: 1 site, Italy
Primary endpoint: GH and IGF-I age-normalized levels, percent GH and IGF-I suppression and percent tumor shrinkage after 3 months

View Octreotide compound reference